92 results found.
        
Enabling Technology and Integrated Selling Strategies Drove Orthopedic Growth in the Third Quarter
The third quarter of 2019 brought some standout performances from large players like Stryker, Medtronic, NuVasive and Globus Medical. DePuy Synthes and Zimmer Biomet made incremental progress in returning to market growth. Notably, the top performing players all have well-established enabling tec...
SI-BONE Continues Growth with Reimbursement Wins
SI-BONE reports 3Q19 revenue of USD $16.2MM, +20.9% vs. 3Q18.
CMS Increases Medicare Physician Payment for Minimally Invasive SI Joint Fusion
CMS increased the Medicare Physician Fee Schedule for CPT® Code 27279, Arthrodesis Sacroiliac Joint, under which minimally invasive sacroiliac j...
SI-BONE 5-Year iFuse Study Results
SI-BONE reports that 5-year follow-up from studies of the iFuse implant for SI joint fusion showed excellent durability of clinical responses and positive radiographic outcomes...
Orthopedic Public Companies Grow 2.6% YoY in Quarter
By Mike Evers The second quarter of 2019 brought incremental improvement over the first. Year over year revenue grew 2.6% in the quarter for the public companies reported herein compared to 1.1% last quarter. The five largest orthopedic players, which control 58% of the market, showed a...
SI-BONE Announces New Positive Coverage for MIS SI Joint Fusion using iFuse
Wellmark Blue Cross Blue Shield established positive coverage for minimally invasive surgical sacroiliac joint fusion using SI-BONE's
SI-BONE Continues Growth in 2Q19 on Payor Coverage
SI-BONE reports 2Q19 revenue of USD $16.3MM, +19.4% vs. 2Q18.
The Spine Market: A Look at Past and Forecasted Performance
By Mike Evers, ORTHOWORLD  Spine is the largest individual segment that we track, accounting for 18.2% of the orthopedic industry’s overall revenue. Excluding biologics, sales of orthopedic spine products topped $9.3 billion in 2018, growing +2.7% vs. 2017. Growth in the segment ...
SI-BONE’s iFuse Surpasses 40,000 Procedures
SI-BONE's iFuse Implant System®, introduced in 2009, has been used in >40,000 SI joint fusion procedures by more than 1,900 surgeons worldwide.
Orthopedic Sales in Line with Seasonal Expectations for 1Q19
By Mike Evers The first quarter of 2019 brought modest growth to the orthopedic market, as expected seasonal softness and more competition in digital surgery platforms slowed sales for some of the largest players. The 25 companies listed herein had combined total orthopedic sales of $8....
SI-BONE Reports 1Q19 Revenue of $15MM, +17.9% vs. 1Q18
SI-BONE reports 1Q19 revenue of USD $15MM, +17.9% vs. 1Q18.
SI-BONE Gains FDA Clearance of iFuse Bedrock Fixation Technology
SI-BONE received an additional FDA 510(k) clearance for use of iFuse Bedrock™ technology in fusion of the sa...
Revenue Review: 4Q18 and Full Year 2018 Performance Highlights for Public Companies
By Mike Evers Below you’ll find a summary of the major 4Q18 and full year 2018 developments for publicly-traded orthopedic companies. Exhibits 1 and 2 show 4Q18 and full year performance, respectively.  Companies continue to refine their strategies to improve sales mix ...
SI-BONE reports 4Q18 revenue of $15.6MM, +13% vs. 4Q17
SI-BONE reports 4Q18 revenue of USD $15.6MM, +13% vs. 4Q17, with 2018 full year revenue of
Alphatec Spine, NuVasive, SeaSpine, SI-BONE and Wright Medical Report Preliminary 4Q18 and FY 2018 Results
Alphatec Spine, NuVasive, SeaSpine, SI-BONE and Wright Medical reported preliminary 4Q18 and FY 2018 results.
Blue Cross Blue Shield of Arizona Covers SI BONE iFuse Implant System
SI-BONE’s iFuse Implant System received exclusive coverage from Blue Cross Blue Shield of Arizona.
SI-BONE reports 3Q18 revenue of $13.4MM, +14.5% vs. 3Q17
SI-BONE reports 3Q18 revenue of US $13.4MM, +14.5% vs. 3Q17.
SI-BONE Closes Initial Public Offering
SI-BONE closed its previously-announced initial public offering of 8,280,000 shares of common stock, priced at US $15 per share. The compan...
SI-BONE Announces UK Guidance Recommendation for iFuse
The U.K.'s National Institute for Health and Care Excellence published medical technology guidance recommending SI-BONE's iFuse
SI-BONE Files for Proposed IPO
SI-BONE publicly filed for a proposed IPO, and applied to list on NASDAQ as SIBN. Proceeds will primarily support commercialization
SI-BONE Gains Exclusive Positive Coverage for iFuse in France
SI-BONE's iFuse® system for sacroiliac joint fusion will be added to the List of Refundable Products and Services ...
RTI's Simmetry Reduces SI Joint Range of Motion
Study results demonstrate that RTI Surgical's Simmetry® Sacroiliac Joint Fusion system provided effective joint fixation, marke...
RTI Surgical Acquiring Zyga Technology
RTI Surgical entered into an agreement to acquire Zyga Technology, developer of the SImmetry® Sacroiliac Joint Fusion s...
Highmark Now Covers Zyga SI Fusion System
U.S. insurer Highmark now covers all U.S. FDA-cleared instrumentation for SI joint fusion, including cages or screws, with or without b...
SI-BONE Maintains Exclusive Positive Coverage with Blue Cross and Blue Shield
Blue Cross and Blue Shield has updated its coverage policy for MIS SI joint fusion in various states, and maint...
  • ORTHOWORLD INC.
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2019 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group